专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2011104621A1 SURFACTANT COMPOSITION 审中-公开
标题翻译：表面活性剂组合物
公开(公告)号：WO2011104621A1
公开(公告)日：2011-09-01
申请号：PCT/IB2011/000394
申请日：2011-02-25
申请人： STELLENBOSCH UNIVERSITY , SMITH, Johan , VAN ZYL, Johann, Martin , VAN DER BIJL, Pieter , HAWTREY, Arthur, Owen
发明人： SMITH, Johan , VAN ZYL, Johann, Martin , VAN DER BIJL, Pieter , HAWTREY, Arthur, Owen
IPC分类号： A61K38/16 , A61K31/683 , A61P11/00
CPC分类号： A61K31/683 , A61K9/0082 , A61K38/02 , A61K38/16
摘要： The invention describes a composition comprising a lipidaceous carrier and a peptide complex formed from poly-L-lysine or a salt thereof; and either poly- L-glutamic acid or poly-L-aspartic acid, or a salt thereof. The composition can be used to prevent or treat a condition related to pulmonary surfactant dysfunction or deficiency, such as hyaline membrane disease (HMD), respiratory distress syndrome (RDS), hydrocarbon poisoning, near-drowning, HIV/AIDS-related lung diseases, adult respiratory distress syndrome (ARDS) or acue lung injury (ALI), asthma, tuberculosis (TB) or severe acute respiratory syndrome (SARS). Alternatively, the composition can be used to increase the permeability of a pharmaceutical compound or composition across a membrane of a subject or to act as a carrier. The poly-L-lysine or salt thereof is longer than the poly-L-glutamic acid or poly-L-aspartic acid so that the complex that forms has a charge-neutralised region and a positively- charged region. The charge-neutralised region of the peptide complex interacts with the lipidaceous carrier, while the positively-charged region interacts with an aqueous and/or polar environment.
摘要翻译：本发明描述了一种包含脂质载体和由聚-L-赖氨酸或其盐形成的肽复合物的组合物; 和聚-L-谷氨酸或聚-L-天冬氨酸或其盐。该组合物可用于预防或治疗与肺表面活性物质功能障碍或缺陷有关的病症，如透明膜疾病（HMD），呼吸窘迫综合征（RDS），碳氢化合物中毒，近溺水，艾滋病毒/艾滋病相关肺部疾病，成人呼吸窘迫综合征（ARDS）或脊髓损伤（ALI），哮喘，结核病（TB）或严重急性呼吸综合征（SARS）。或者，组合物可以用于增加药物化合物或组合物穿过受试者的膜或作为载体的渗透性。聚-L-赖氨酸或其盐比聚-L-谷氨酸或聚-L-天冬氨酸长，使得形成的络合物具有电荷中和区域和带正电荷区域。肽络合物的电荷中和区域与脂质载体相互作用，而带正电荷的区域与水性和/或极性环境相互作用。

32. 发明申请

WO2011084610A1 LIPOSOMES FOR PREVENTING THE SPREAD OF HIV 审中-公开
标题翻译：用于预防艾滋病毒蔓延的药物
公开(公告)号：WO2011084610A1
公开(公告)日：2011-07-14
申请号：PCT/US2010/060790
申请日：2010-12-16
申请人： CHILDREN MEDICAL CENTER CORPORATION , MASSACHUSETTS INSTITUTE OF TECHNOLOGY , MALAVIA, Nikita, Kiran , KOHANE, Daniel, S.
发明人： MALAVIA, Nikita, Kiran , KOHANE, Daniel, S.
IPC分类号： A61K31/683 , A61K45/06 , A61K9/127 , A61K47/48 , A61P31/18
CPC分类号： A61K31/683 , A61K9/127 , A61K45/06 , A61K2300/00
摘要： Formulations for preventing the sexual transmission of the HIV virus are provided. In one embodiment, the formulations contain unconjugated liposomes whose physicochemical properties allow binding to the HIV virus. The liposomes are made up of natural or synthetic lipids, alone or in combination. Preferably, the liposomes are made entirely of cardiolipin. In other embodiments the liposomes are modified to contain Hgands which bind HIV. The method for preventing the sexual transmission of the HIV virus includes self-administration of a formulation containing an effective amount of liposomes which bind to the HIV virus to the surface of a mucosal membrane prior to intercourse.
摘要翻译：提供了防止HIV病毒性传播的制剂。在一个实施方案中，制剂含有非结合的脂质体，其物理化学性质允许与HIV病毒结合。脂质体单独或组合由天然或合成的脂质组成。优选地，脂质体完全由心磷脂制成。在其它实施方案中，将脂质体修饰成含有结合HIV的Hg。防止HIV病毒性传播的方法包括在性交前将包含有效量的结合HIV病毒的脂质体的制剂自主给药至粘膜表面。

33. 发明申请

WO2011083467A1 COMBINED TREATMENT UTILIZING VB-201 审中-公开
标题翻译：使用VB-201的组合治疗
公开(公告)号：WO2011083467A1
公开(公告)日：2011-07-14
申请号：PCT/IL2011/000010
申请日：2011-01-05
申请人： VASCULAR BIOGENICS LTD. , COHEN, Yael , YACOV, Niva , BREITBART, Eyal
发明人： COHEN, Yael , YACOV, Niva , BREITBART, Eyal
IPC分类号： A61K45/00
CPC分类号： A61K31/685 , A61K31/198 , A61K31/366 , A61K31/40 , A61K31/505 , A61K31/683 , A61K38/02 , A61K45/06 , Y02A50/414
摘要： Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.
摘要翻译：本文描述了利用氧化脂质VB-201与另外的治疗活性剂共同给药的治疗方法。本文描述了治疗心血管疾病的方法，包括将VB-201和他汀类药物共同给予对他汀类药物不完全反应的受试者以及治疗炎性疾病或病症的方法，包括共同给予 VB-201和醋酸格拉默。本文还描述了一种包含鉴定为与醋酸格拉默组合使用的VB-201的药物组合物。还描述了确定受试者中治疗有效量的VB-201和确定治疗有效量的用于与另外的治疗活性剂共同施用的VB-201的方法。还公开了VB-201的新型单位剂型及其利用方法。

34. 发明申请

WO2011071981A2 ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS 审中-公开
标题翻译：阿司匹林衍生二聚体的抗细胞因子活性
公开(公告)号：WO2011071981A2
公开(公告)日：2011-06-16
申请号：PCT/US2010/059390
申请日：2010-12-08
申请人： THE JOHNS HOPKINS UNIVERSITY , ARAV-BOGER, Ravit , POSNER, Gary
发明人： ARAV-BOGER, Ravit , POSNER, Gary
IPC分类号： A61K31/35 , A61K31/357 , A61P31/12 , A61P35/00
CPC分类号： A61K31/357 , A61K31/683 , A61K45/06 , C07D493/18 , C07F9/6561
摘要： Artemisinin-derived monomers and artemisinin dimers are shown to exhibit in-vitro anti-cytomegalovirus (CMV) activity. Artemisinin dimers effectively inhibited CMV replication in human foreskin fibroblasts and human embryonic lung fibroblasts with no cytotxicity at concentrations required for complete CMV inhibition. Artemisinin dimers were found to be potent and non-cytotoxic inhibitors of CMV replication, which indicates their use as therapeutic agents for the treatment of CMV infection in humans.
摘要翻译：青蒿素衍生的单体和青蒿素二聚体显示出体外抗巨细胞病毒（CMV）活性。青蒿素二聚体有效抑制人包皮成纤维细胞和人胚胎肺成纤维细胞中的CMV复制，在完全CMV抑制所需的浓度下无细胞毒性。青蒿素二聚体被发现是CMV复制的有效和非细胞毒性抑制剂，这表明它们用作治疗人类CMV感染的治疗剂。

35. 发明申请

WO2010128717A1 콜린성 제２형 세타리듬을 이용한 불안장애 예방 또는 치료를 위한 약물 적합성 판정 방법 审中-公开
标题翻译：使用胆固醇II型THETA RHYTHM预防或治疗无效性疾病的药物适应性评估方法
公开(公告)号：WO2010128717A1
公开(公告)日：2010-11-11
申请号：PCT/KR2009/004583
申请日：2009-08-17
申请人： 한국과학기술연구원 , 신희섭 , 신종한 , 강가다란기리쉬 , 김성욱 , 김덕수 , 이수경 , 김연수
发明人： 신희섭 , 신종한 , 강가다란기리쉬 , 김성욱 , 김덕수 , 이수경 , 김연수
IPC分类号： A61K31/27
CPC分类号： A61K31/27 , A61B5/0476 , A61K31/12 , A61K31/14 , A61K31/165 , A61K31/407 , A61K31/435 , A61K31/4425 , A61K31/445 , A61K31/473 , A61K31/553 , A61K31/683 , A61K49/0004
摘要： 본 발명은 콜린성 제2형 세타리듬(cholinergic type Ⅱ theta rhythm)을 이용한 불안장애 예방 또는 치료를 위한 약물 적합성 판정 방법에 관한 것으로, 보다 상세하게는 불안증 동물 모델에서 콜린성 제2형 세타리듬이 정상개체에 비해 감소하고, 콜린성 약물 처리에 의해 콜린성 제2형 세타리듬이 정상적으로 회복되고 불안증이 감소하는 것을 확인함으로써 콜린성 제2형 세타리듬 프로파일을 이용하여 콜린성 시스템에 이상이 생겨서 유발되는 불안장애 개체를 찾을 수 있으므로 콜린성 약물 투여가 적절한 개체를 판단할 수 있으며, 콜리성 약물 처리 후 경과를 모니터링하는데 사용할 수 있다.
摘要翻译：本发明涉及使用胆碱能型IIθ节律预防或治疗焦虑症的药物适应性评价方法，更具体地说，涉及一种检测患有由胆碱能系统发生的异常引起的焦虑障碍的个体的方法使用基于动物焦虑模型中胆碱能型IIθ节律低于正常受试者的发现的类型IIθ节律谱，并且胆碱能药物治疗诱导胆碱能II型心律恢复正常并减少焦虑，从而可以确定个体是否可以适当地施用胆碱能药物并监测胆碱能药物治疗后的进展。

36. 发明申请

WO2010099580A1 TREATMENT OF INFECTION 审中-公开
标题翻译：感染治疗
公开(公告)号：WO2010099580A1
公开(公告)日：2010-09-10
申请号：PCT/AU2010/000255
申请日：2010-03-05
申请人： MCCLOSKEY, Jenny Colleen
发明人： MCCLOSKEY, Jenny Colleen
IPC分类号： A61K33/08 , A61K39/39 , A61P31/12
CPC分类号： A61K39/39 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K31/661 , A61K31/683 , A61K33/08 , A61K39/12 , A61K45/06 , A61K2039/54 , A61K2039/55505 , A61K2039/55572 , A61M31/00 , A61M2210/14 , C12N7/00 , C12N2710/00034 , C12N2710/20034 , A61K2300/00
摘要： The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal.
摘要翻译：本发明涉及包含可用作增强免疫应答的佐剂的物质的组合物，以及在转化区域或子宫颈或肛管转化区内或附近的组织感染个体中使用该组合物的方法。

37. 发明申请

WO2010077613A1 MODULATORS OF TOLL-LIKE RECEPTORS 审中-公开
标题翻译：类似受体的调节剂
公开(公告)号：WO2010077613A1
公开(公告)日：2010-07-08
申请号：PCT/US2009/067002
申请日：2009-12-07
申请人： GILEAD SCIENCES, INC. , DESAI, Manoj, C. , HALCOMB, Randall, L. , HRVATIN, Paul , HUI, Hon Chung , MC FADDEN, Ryan , ROETHLE, Paul, A. , YANG, Hong
发明人： DESAI, Manoj, C. , HALCOMB, Randall, L. , HRVATIN, Paul , HUI, Hon Chung , MC FADDEN, Ryan , ROETHLE, Paul, A. , YANG, Hong
IPC分类号： C07D475/06 , C07D475/08 , C07D475/12 , C07D487/04 , A61K31/519 , A61P31/12 , A61P35/00
CPC分类号： A61K31/519 , A61K31/527 , A61K31/5377 , A61K31/551 , A61K31/573 , A61K31/683 , A61K31/7056 , A61K31/7072 , A61K31/708 , A61K38/16 , A61K38/21 , A61K38/212 , A61K45/06 , C07D403/12 , C07D475/06 , C07D475/08 , C07D475/10 , C07D475/12 , C07D487/04 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/391 , Y02A50/393 , Y02A50/395
摘要： Provided are modulators of TLRs of Formula (II): pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
摘要翻译：提供式（II）的TLR的调节剂：其药学上可接受的盐，含有这些化合物的组合物和包括施用这些化合物的治疗方法。

38. 发明申请

WO2010046540A1 NUCLEIC ACID BINDING PEPTIDE 审中-公开
标题翻译：核酸结合肽
公开(公告)号：WO2010046540A1
公开(公告)日：2010-04-29
申请号：PCT/FI2009/050854
申请日：2009-10-23
申请人： VIIRI, Keijo , LOHI, Olli , MÄKI, Markku
发明人： VIIRI, Keijo , LOHI, Olli , MÄKI, Markku
IPC分类号： C07K14/47 , A61K31/683 , A61P31/16 , A61P31/18 , A61P35/00 , C07F9/10 , C07F9/117
CPC分类号： A61K31/683 , C07K14/4703
摘要： The present invention relates to means and methods for regulating gene expression. Specifically the invention relates to the use of said phospholipids for detaching zinc finger proteins from chromatin/DNA. Furthermore, the invention relates to a method for nucleic acid binding.
摘要翻译：本发明涉及调节基因表达的方法和方法。具体地，本发明涉及所述磷脂用于从锌染色质/ DNA分离锌指蛋白的用途。此外，本发明涉及核酸结合方法。

39. 发明申请

WO2009037398A2 FOODSTUFF COMPOSITION TO IMPROVE DIGESTIBILITY OF FOODSTUFF LIPIDS 审中-公开
标题翻译：食品组合物提高食品添加剂的可食用性
公开(公告)号：WO2009037398A2
公开(公告)日：2009-03-26
申请号：PCT/FR2008001062
申请日：2008-07-18
申请人： ISL INNOVATION SANTE LIPIDES , INST NAT SANTE RECH MED , ARMAND MARTINE , PIERONI GERARD
发明人： ARMAND MARTINE , PIERONI GERARD
IPC分类号： A23L1/30 , A61K31/66 , A61K31/683 , A61K31/685 , A61P3/02
CPC分类号： A23K20/158 , A23L33/115 , A61K31/66 , A61K31/683 , A61K31/685
摘要： The invention relates to human or animal food and more particularly to a food composition for improving digestibility of foodstuff lipids, comprising one or more lysophospholipids and/or phospholipids. The invention further relates to a foodstuff containing said food composition and a method for improving the digestibility of foodstuff lipids.
摘要翻译：本发明涉及人或动物食品，更具体地涉及一种用于改善食用脂质消化率的食品组合物，其包含一种或多种溶血磷脂和/或磷脂。本发明还涉及含有所述食品组合物的食品和改善食用脂质的消化率的方法。

40. 发明申请

WO2008106772A1 PHOSPHOLIPID COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS FOR THEIR USE 审中-公开
标题翻译：具有改善生物利用度的磷脂组合物及其使用方法
公开(公告)号：WO2008106772A1
公开(公告)日：2008-09-12
申请号：PCT/CA2008/000399
申请日：2008-03-03
申请人： LIPONEX, INC. , SOKOLL, Kenneth, K. , SPARKS, Daniel, L.
发明人： SOKOLL, Kenneth, K. , SPARKS, Daniel, L.
IPC分类号： A61K31/683 , A61K36/48 , A61K45/00 , A61K9/32 , A61K9/36 , A61K9/52 , A61P3/06 , A61P9/10
CPC分类号： A61K36/48 , A61K9/1617 , A61K9/1652 , A61K9/2846 , A61K9/4891 , A61K9/5026 , A61K31/683
摘要： The invention provides pharmaceutical compositions for oral administration comprising a phospholipid having an enteric coating, in an effective amount for treating or preventing dyslipidemia or atherosclerosis. Methods of using these compositions are also provided. Also provided is a method wherein the above -described phospholipid is administered in combination with an antacid agent or proton pump inhibitor.
摘要翻译：本发明提供用于口服给药的药物组合物，其包含具有肠溶衣的磷脂，其用量用于治疗或预防血脂异常或动脉粥样硬化。还提供了使用这些组合物的方法。还提供了一种方法，其中将上述描述的磷脂与抗酸剂或质子泵抑制剂组合施用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式